drugset / Trial / NCT03040323

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

NCT03040323

Phase 4 Terminated 83 enrolled Indiana University
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.

Timeline

Start
2016-12-22
Primary completion
2018-06-30
Completion
2018-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumason Diagnostic / imaging agent 60.7 mg Other

Indications

No indication recorded.